Erasca, Inc.
NASDAQ:ERASBiotechnology
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
Volume 8.94M
Average 6.79M
ERAS Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Erasca, Inc.NASDAQ: ERAS
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses growth accelerates
Q3 FY2026 other income / expenses of $8.19M rose 108.2% year over year, ahead of the -898.0% change in trailing-twelve-month other income / expenses. Sequentially, it rose 131.4% from the prior quarter. Over 3 fiscal years it compounded at +13.9% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +108.2% holds above the trailing-twelve-month pace of -898.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 6.86M USD
- Year-over-year change
- -61.8%
- 4-year CAGR
- +34.1%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.86M | -61.8% |
| FY2024 | 2024-12-31 | 17.94M | +8.8% |
| FY2023 | 2023-12-31 | 16.48M | +254.9% |
| FY2022 | 2022-12-31 | 4.65M | +119.2% |
| FY2021 | 2021-12-31 | 2.12M | — |
Other Income / Expenses vs competitors
How ERAS compares with its peers on the latest reported figures
- ERAS's LTM Sep 2026 other income / expenses of -$130.29M is the 8th highest of the 9 companies compared; the peer median is $13.16M.
- Its year-over-year change of -898.0% is the lowest of 9, against a peer median of -14.9%.
- Over three fiscal years its annual growth of +13.9% compares with a peer median of +74.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $43.41M | -19.7% | +128.0% | 19.3% | |
| LTM Mar 2026 | $23.26M | -2.3% | +84.5% | 32.5% | |
| LTM Sep 2026 | $20.48M | +106.3% | +48.7% | — | |
| LTM Mar 2026 | $14.69M | +6.7% | +72.3% | — | |
| LTM Mar 2026 | $11.63M | -10.2% | — | — | |
| LTM Jun 2026 | -$12.2M | -156.1% | -18.4% | 7.2% | |
| LTM Mar 2026 | -$23.11M | -31.1% | — | 46.6% | |
| LTM Sep 2026 | -$130.29M | -898.0% | +13.9% | — | |
| LTM Jun 2026 | -$141.04M | -266.5% | +77.4% | — | |
| Peer median (excluding ERAS) | $13.16M | -14.9% | +74.8% | 25.9% | |
Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 829K | 2.64M | 3.73M | 0 | 3.11M |
| Gross Profit | (829K) | (2.64M) | (3.73M) | 0 | (3.11M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 73.92M | 112.46M | 103.82M | 115.36M | 92.85M |
| Selling, General & Admin | 22.62M | 32.99M | 37.7M | 41.73M | 38.55M |
| Operating Expenses | 124.05M | 244.81M | 137.79M | 179.59M | 128.3M |
| Depreciation & Amortization | 829K | 2.64M | 3.73M | 3.81M | 3.11M |
| EBITDA | (121.94M) | (240.16M) | (121.31M) | (153.28M) | (121.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (124.88M) | (247.45M) | (141.53M) | (179.59M) | (131.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 190K | 4.9M | 16.71M | 20.09M | 16.61M |
| Interest Expense | 0 | 201.36M | 0 | 0 | 0 |
| Other Income / Expenses | 2.12M | 4.65M | 16.48M | 17.94M | 6.86M |
| Income Before Tax | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (1.99) | (0.83) | (0.69) | (0.44) |
| EPS (Diluted) | (1.03) | (1.99) | (0.83) | (0.69) | (0.44) |
| Weighted Avg Shares | 119.1M | 122.02M | 150.18M | 233.82M | 283.53M |
| Weighted Avg Shares (Diluted) | 119.1M | 122.02M | 150.18M | 233.82M | 283.53M |
Erasca, Inc.
NASDAQ:ERAS
Intrinsic Alpha fair value
Locked
Current Price
$13.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.